Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vinblastine Sulfate

FDA-approved product (injectable, injection), marketed as Velban, Vinblastine Sulfate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vinblastine Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Classic Hodgkin lymphoma
  • Fungal infectious disease
  • Hodgkins lymphoma
  • Lymphoid neoplasm
  • Lymphoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Vinca alkaloids and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis70.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vinblastine Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vinblastine Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy

    NCT03527628 · start 2018-01-01

    Registered record
    Registry ID
    NCT03527628
    Conditions
    Classical Hodgkin Lymphoma; Hodgkin Lymphoma (Category); Hodgkin Disease; Hodgkin Lymphoma
    Interventions
    Adriamycin; Cyclophosphamide; Vinblastine; Dacarbazine; Brentuximab Vedotin; ABVD
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-01-01
    Completion
    2022-01-15
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClassical Hodgkin Lymphoma; Hodgkin Lymphoma (Category); Hodgkin Disease; Hodgkin Lymphoma
    InterventionAdriamycin; Cyclophosphamide; Vinblastine; Dacarbazine +2 more
    PhasePhase 2
    Registry statusUnknown

  • Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.

    NCT02292979 · start 2015-03

    Registered record
    Registry ID
    NCT02292979
    Conditions
    Hodgkin Lymphoma
    Interventions
    Doxorubicin; Bleomycin; Vinblastine; Dacarbazine; Brentuximab Vedotin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-03
    Completion
    2022-06-02
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin Lymphoma
    InterventionDoxorubicin; Bleomycin; Vinblastine; Dacarbazine +1 more
    PhasePhase 2
    Registry statusCompleted

  • SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

    NCT02299999 · start 2014-04-07

    Registered record
    Registry ID
    NCT02299999
    Conditions
    Metastatic Breast Cancer
    Interventions
    AZD2014; AZD4547; AZD5363; AZD8931; Selumetinib; Vandetanib; Bicalutamide; Olaparib; Anthracyclines; Taxanes; cyclophosphamide; DNA intercalators; Methotrexate; vinca alkaloids; Platinum based chemotherapies; Bevacizumab; Mitomycin C; Eribulin; MEDI4736
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2014-04-07
    Completion
    2025-12
    Enrolment
    1,460

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionAZD2014; AZD4547; AZD5363; AZD8931 +15 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Brentuximab Vedotin with Adriamycin, Vinblastine and Dacarbazine for Patients Aged 18-59 Years with Untreated Advanced-stage Classical Hodgkin Lymphoma: a Real-life Experience

    NCT06857500 · start 2013-01-01

    Registered record
    Registry ID
    NCT06857500
    Conditions
    Classic Hodgkin Lymphoma; Advanced Hodgkin Lymphoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-01-01
    Completion
    2025-01-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClassic Hodgkin Lymphoma; Advanced Hodgkin Lymphoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

    NCT01712490 · start 2012-11-09

    Registered record
    Registry ID
    NCT01712490
    Conditions
    Hodgkin Lymphoma
    Interventions
    brentuximab vedotin; doxorubicin; bleomycin; vinblastine; dacarbazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-11-09
    Completion
    2026-02-02
    Enrolment
    1,334

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin Lymphoma
    Interventionbrentuximab vedotin; doxorubicin; bleomycin; vinblastine +1 more
    PhasePhase 3
    Registry statusCompleted

  • Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma

    NCT02247869 · start 2012-02

    Registered record
    Registry ID
    NCT02247869
    Conditions
    Hodgkin Lymphoma
    Interventions
    dose dense ABVD
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-02
    Completion
    2017-04-29
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin Lymphoma
    Interventiondose dense ABVD
    PhasePhase 2
    Registry statusCompleted

  • Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

    NCT01196416 · start 2010-08

    Registered record
    Registry ID
    NCT01196416
    Conditions
    Recurrent Melanoma; Stage IV Skin Melanoma
    Interventions
    Cisplatin; Gamma-Secretase Inhibitor RO4929097; Laboratory Biomarker Analysis; Pharmacological Study; Temozolomide; Vinblastine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2010-08
    Completion
    2015-08
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Melanoma; Stage IV Skin Melanoma
    InterventionCisplatin; Gamma-Secretase Inhibitor RO4929097; Laboratory Biomarker Analysis; Pharmacological Study +2 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

    NCT01056679 · start 2010-04

    Registered record
    Registry ID
    NCT01056679
    Conditions
    Hodgkin Lymphoma
    Interventions
    Doxorubicine; DTIC; Lenalidomide; Vinblastine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-04
    Completion
    2016-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin Lymphoma
    InterventionDoxorubicine; DTIC; Lenalidomide; Vinblastine
    PhasePhase 1
    Registry statusCompleted

  • A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

    NCT01060904 · start 2010-01

    Registered record
    Registry ID
    NCT01060904
    Conditions
    Disease, Hodgkin
    Interventions
    brentuximab vedotin; doxorubicin; vinblastine; dacarbazine; bleomycin; brentuximab vedotin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-01
    Completion
    2012-09
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDisease, Hodgkin
    Interventionbrentuximab vedotin; doxorubicin; vinblastine; dacarbazine +2 more
    PhasePhase 1
    Registry statusCompleted

  • Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma

    NCT01088750 · start 2009-11-01

    Registered record
    Registry ID
    NCT01088750
    Conditions
    Lymphoma
    Interventions
    cyclophosphamide; prednisolone; vinblastine sulfate; watchful waiting; therapeutic conventional surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-11-01
    Completion
    2023-10-31
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventioncyclophosphamide; prednisolone; vinblastine sulfate; watchful waiting +1 more
    PhasePhase 4
    Registry statusCompleted

  • Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma

    NCT00901303 · start 2008-10

    Registered record
    Registry ID
    NCT00901303
    Conditions
    Hodgkin's Lymphoma
    Interventions
    ABVD chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2008-10
    Completion
    2011-05-23
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin's Lymphoma
    InterventionABVD chemotherapy
    PhaseNot applicable
    Registry statusTerminated

  • Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

    NCT00678327 · start 2008-08-29

    Registered record
    Registry ID
    NCT00678327
    Conditions
    Lymphoma
    Interventions
    bleomycin sulfate; filgrastim; pegfilgrastim; cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide; prednisolone; procarbazine hydrochloride; vinblastine sulfate; vincristine sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-08-29
    Completion
    2024-05-01
    Enrolment
    1,202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionbleomycin sulfate; filgrastim; pegfilgrastim; cyclophosphamide +7 more
    PhasePhase 3
    Registry statusCompleted

  • Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers

    NCT00498979 · start 2007-05

    Registered record
    Registry ID
    NCT00498979
    Conditions
    Stage IV Melanoma
    Interventions
    recombinant interferon alfa-2b; cisplatin; sodium stibogluconate; dacarbazine; vinblastine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-05
    Completion
    2012-01
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage IV Melanoma
    Interventionrecombinant interferon alfa-2b; cisplatin; sodium stibogluconate; dacarbazine +1 more
    PhasePhase 1
    Registry statusCompleted

  • Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma

    NCT00673361 · start 2007-03

    Registered record
    Registry ID
    NCT00673361
    Conditions
    Melanoma
    Interventions
    Concurrent decrescendo biochemotherapy regimen; Low-dose Temozolomide plus Sorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-03
    Completion
    2009-01
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionConcurrent decrescendo biochemotherapy regimen; Low-dose Temozolomide plus Sorafenib
    PhasePhase 2
    Registry statusTerminated

  • Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

    NCT00412425 · start 2006-11

    Registered record
    Registry ID
    NCT00412425
    Conditions
    Melanoma
    Interventions
    Palonosetron
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2006-11
    Completion
    2009-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionPalonosetron
    PhasePhase 1 / Phase 2
    Registry statusCompleted